PSA has been proposed as a tumour marker for prostate adenocarcinoma, the levels providing an indication of disease volume and biological activity, such that a fall in PSA indicates a potential beneficial effect (Kelly et al, 1993; Sartor et al, 1998). This evidence concerns the gene KLK3 and prostate adenocarcinoma.